Kwang Hwa Jung1, Jing Zhang1, Chong Zhou1, Hong Shen1, Mihai Gagea2, Cristian Rodriguez-Aguayo3, Gabriel Lopez-Berestein3, Anil K Sood4, Laura Beretta1. 1. Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. 2. Department of Veterinary Medicine & Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX. 3. Department of Experimental Therapeutics and the Center for RNAi and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX. 4. Department of Gynecologic and Reproductive Oncology and the Center for RNAi and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX.
Abstract
UNLABELLED: The death rate from hepatocellular carcinoma (HCC) is increasing, and liver cancer is the second leading cause of cancer-related mortality worldwide. Most patients with HCC have underlying liver cirrhosis and compromised liver function, limiting treatment options. Cirrhosis is associated with cell dedifferentiation and expansion of hepatocholangiolar progenitor cells. We identified a microRNA signature associated with HCC and hepatocytic differentiation of progenitor cells. We further identified miR-148a as an inducer of hepatocytic differentiation that is down-regulated in HCC. MiR-148a-mimetic treatment in vivo suppressed tumor growth, reduced tumor malignancy and liver fibrosis, and prevented tumor development. These effects were associated with an increased differentiated phenotype and mediated by IκB kinase alpha/NUMB/NOTCH signaling. CONCLUSION: miR-148a is an inhibitor of the IκB kinase alpha/NUMB/NOTCH pathway and an inducer of hepatocytic differentiation that when deregulated promotes HCC initiation and progression. Differentiation-targeted therapy may be a promising strategy to treat and prevent HCC.
UNLABELLED: The death rate from hepatocellular carcinoma (HCC) is increasing, and liver cancer is the second leading cause of cancer-related mortality worldwide. Most patients with HCC have underlying liver cirrhosis and compromised liver function, limiting treatment options. Cirrhosis is associated with cell dedifferentiation and expansion of hepatocholangiolar progenitor cells. We identified a microRNA signature associated with HCC and hepatocytic differentiation of progenitor cells. We further identified miR-148a as an inducer of hepatocytic differentiation that is down-regulated in HCC. MiR-148a-mimetic treatment in vivo suppressed tumor growth, reduced tumor malignancy and liver fibrosis, and prevented tumor development. These effects were associated with an increased differentiated phenotype and mediated by IκB kinase alpha/NUMB/NOTCH signaling. CONCLUSION: miR-148a is an inhibitor of the IκB kinase alpha/NUMB/NOTCH pathway and an inducer of hepatocytic differentiation that when deregulated promotes HCC initiation and progression. Differentiation-targeted therapy may be a promising strategy to treat and prevent HCC.
Authors: Erik G Huntzicker; Kathy Hötzel; Lisa Choy; Li Che; Jed Ross; Gregoire Pau; Neeraj Sharma; Christian W Siebel; Xin Chen; Dorothy M French Journal: Hepatology Date: 2015-01-28 Impact factor: 17.425
Authors: Nicholas J Hand; Zankhana R Master; Steven F Eauclaire; Daniel E Weinblatt; Randolph P Matthews; Joshua R Friedman Journal: Gastroenterology Date: 2008-12-09 Impact factor: 22.682
Authors: Jungeun Kim; Ying Zhang; Michael Skalski; Josie Hayes; Benjamin Kefas; David Schiff; Benjamin Purow; Sarah Parsons; Sean Lawler; Roger Abounader Journal: Cancer Res Date: 2014-01-14 Impact factor: 12.701
Authors: Michael T Dill; Luigi Tornillo; Thorsten Fritzius; Luigi Terracciano; David Semela; Bernhard Bettler; Markus H Heim; Jan S Tchorz Journal: Hepatology Date: 2013-03-14 Impact factor: 17.425
Authors: Kwang Hwa Jung; Wonbeak Yoo; Heather L Stevenson; Dipti Deshpande; Hong Shen; Mihai Gagea; Suk-Young Yoo; Jing Wang; T Kris Eckols; Uddalak Bharadwaj; David J Tweardy; Laura Beretta Journal: Clin Cancer Res Date: 2017-05-22 Impact factor: 12.531